title: Reduced susceptibility of Malaysian clinical isolates of Burkholderia pseudomallei to ciprofloxacin.
abstract: Ciprofloxacin, a quinolone with good intracellular penetration may possibly be   used for treatment of melioidosis caused by Burkholderia pseudomallei, but problems with   resistance may be encountered. Amino acid substitutions in gyrA/gyrB have given rise to   fluoroquinolone resistance in various microorganisms. Using published primers for gyrA and   gyrB, PCR was performed on 11 isolates of B. pseudomallei with varying degrees of sensitivity   to ciprofloxacin, followed by DNA sequencing to detect possible mutations. Results showed   an absence of any point mutation in either gene. Local isolates have yet to develop full   resistance to ciprofloxacin and probably other mechanisms of resistance may have been   involved in the decreased sensitivity to ciprofloxacin.
authors.affiliation: Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
authors.forename: F Y
authors.initials: FY
authors.lastname: Liew
authors.forename: S T
authors.initials: ST
authors.lastname: Tay
authors.forename: S D
authors.initials: SD
authors.lastname: Puthucheary
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016957:Burkholderia pseudomallei / Q000187:drug effects* / Q000302:isolation & purification; D002939:Ciprofloxacin / Q000494:pharmacology*; D027081:DNA Gyrase / Q000235:genetics; D017931:DNA Primers / Q000235:genetics; D024881:Drug Resistance, Bacterial; D006801:Humans; D008296:Malaysia / Q000453:epidemiology; D008554:Melioidosis / Q000453:epidemiology / Q000382:microbiology*; D008826:Microbial Sensitivity Tests / Q000379:methods; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D017422:Sequence Analysis, DNA
chemical_list: D000900:Anti-Bacterial Agents; D017931:DNA Primers; D002939:Ciprofloxacin; D027081:DNA Gyrase